期刊文献+

常见抗菌药物在肥胖人群中剂量换算及临床应用的研究进展 被引量:12

The research on the clinical efficacy of antibiotic therapy and dose adjustments in the obese population
下载PDF
导出
摘要 探讨肥胖特殊人群抗菌药物的合理使用。本文对临床常用的抗菌药物在肥胖人群中临床应用进行汇总,对肥胖的分类、常见的体重指标公式换算、抗菌药物的药动学等均有所涉及。肥胖患者的药动学参数发生改变,要达到目标治疗浓度需进行剂量的调整。肥胖患者在应用抗菌药物过程中,应结合抗菌药物的药动学特性,合理使用抗菌药物。 To explore the rational use of antibiotics in the obese population. In this review, published data regarding several antimicrobial drugs are summarized, including different obesity classifications, body weight descriptions, dosing recommendations of commonly used antibiotics in obesity. The pharmacokinetic parameters of obese patients were different from those of the non-obese patients, and thus the doses should be adjusted to achieve the targeted treatment concentrations. In the application of antibiotics, it is necessary to utilize pharmacokinetic pharmacology parameters of antibiotics to promote the rational use in obese patients.
作者 田婷婷 王加林 宋洪涛 Tian Ting-ting Wang Jia-lin Song Hong-tao(Department of Pharmacy, Fuzhou General Hospital of Nanjing Military Area Command, Fuzhou 350025 Department of Laboratory, Fuzhou General Hospital of Nanjing Military Area Command, Fuzhou 350025)
出处 《中国抗生素杂志》 CAS CSCD 北大核心 2016年第12期893-897,共5页 Chinese Journal of Antibiotics
关键词 肥胖 体重指数 理想体重 校正体重 抗菌药物 剂量调整 Obesity Body mass index Ideal body weight Adjusted body weight Antimicrobial drugs Dosing adjustments
  • 相关文献

参考文献3

二级参考文献57

  • 1李.实用临床药物动力学,第1版[M].成都:四川大学出版社,1997.85.
  • 2Arias C A, Murray B E. Antibiotic-resistant bugs in the 21st century-a clinicial super-challenge[J]. N Eng J Med, 2009, 360(5): 439-443.
  • 3Bradley J S, Dudley M N, Drusano G L. Predicting efficacy of antiinfectives with pharmacodynamics and monte carlo simulation[J]. Pediatr Infect Dis J, 2003, 22(11): 982-992.
  • 4Wang H, Zhang B, Ni Y, et al. Pharmacodynamic target attainment of seven antimicrobials against Gram-negative bacteria collected from China in 2003 and 2004[J]. Int J Antimicrob Agents, 2007, 30(5): 452-457.
  • 5Mouton J W, Dudley M N, Cars O, et al. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update[J]. J Antimicrob Chemother, 2005, 55(5): 601-607.
  • 6Drusano G L. Prevention of resistance: a goal for dose selection for antimicrobial agents[J]. Clin Infect Dis, 2003, 36(Suppl 1): S42-S50.
  • 7Jaruratanasirikul S, Sriwiriyajan S. Stability of meropenem in normal saline solution after storage at room temperature[J], southeast Asian J Trop Med Public Health, 2003, 34(3): 627-629.
  • 8Jaruratanasirikul S, Sriwiriyajan S, Punyo J. Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection[J]. Antimicrob Agents Chemother, 2005, 49(4): 1337-1339.
  • 9Harrison M P, Haworths J, Mosss R, et al. The disposition and metabolic fate of 14C-meropenem in man[J]. Xenobiotica, 1993, 23(11): 1311-1323.
  • 10Bax RP, Bastain W, Featherstone A, et al. The pharmacokinetics of meropenem in volunteers[J]. J Antimicrob Chemother, 1989, 24(suppl A): 311 -320.

共引文献43

同被引文献64

引证文献12

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部